By InvitationNot Applicable

Cardiotoxicity of Cancer Therapy (CCT)

United States700 participantsStarted 2010-07

Plain-language summary

The objective of this study is to define the clinical significance of mechanistic biomarkers (including Neuregulin-1Beta) and novel echocardiographic measures of cardiac function in predicting the incident risk of cancer therapy cardiotoxicity.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or older * HER-2 positive breast cancer designated to receive trastuzumab chemotherapy with or without prior exposure to anthracycline-based chemotherapy * Non-HER-2 positive breast cancer designated to receive treatment with an anthracycline-containing regimen Exclusion Criteria: * Other contraindications to trastuzumab or anthracycline chemotherapy. * Vulnerable populations

What they're measuring

Cardiac dysfunction or signs or symptoms of heart failure

Timeframe: 15 years

Trial details

NCT IDNCT01173341

SponsorAbramson Cancer Center at Penn Medicine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2037-04

View on ClinicalTrials.gov More Breast Cancer trials